Roche has agreed to acquire Anadys Pharmaceuticals and its portfolio of two hepatitis C virus (HCV) drug candidates for US$3.70 per share, which represents a 256% premium over Anadys’ closing price prior to the announcement of the deal and equates to a total consideration of approximately US$230 M. Just 4 days before the agreement was publicised, Anadys reported positive interim safety and efficacy from a Phase IIb clinical study of setrobuvir, its lead HCV drug, in combination with ribavirin and interferon.